FDA Clears Roche's Once-Daily Giredestrant for Hard-to-Treat Breast Cancer
The FDA approved giredestrant, sold as Wilserdly, a once-daily pill taken with everolimus for advanced ER-positive, HER2-negative breast cancer carrying an ESR1 mutation. Trial patients went a median 10 months before their cancer worsened, versus 5.5 months on standard hormone therapy. Roche's list price: about $270,000 a year.
- Original source: clinicaladvisor.com.
- The source published it on Nov 19, 2026 at 8:53 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA cleared giredestrant, brand name Wilserdly, on Monday as a once-daily pill paired with everolimus. The combo is for adults whose estrogen receptor-positive, HER2-negative breast cancer has grown into nearby tissue or spread elsewhere in the body. Crucially, it only covers tumors carrying an ESR1 mutation that let them dodge earlier hormone therapy.
That mutation is common. Roche, which makes the drug, said in a news release that up to 40% of patients with this type of advanced breast cancer develop ESR1 changes. To flag them, the FDA authorized a companion blood test called FoundationOne Liquid CDx, which hunts for fragments of tumor DNA floating in the bloodstream.
The two drugs attack on different fronts. Giredestrant grabs estrogen receptors on cancer cells, blocks estrogen and forces the receptors to break down, while everolimus shuts off a separate growth pathway. The approval leans on a 373-person trial; 207 of those participants had ESR1 mutations, and everyone received everolimus alongside either giredestrant or a doctor-chosen standard hormone therapy.
For patients with the mutation, giredestrant pushed back cancer worsening to a median of 10 months. Standard hormone therapy managed 5.5 months. Tumors shrank in 27% of the giredestrant group versus 14% of the comparison group — though the FDA cautioned it's too early to say whether the pairing extends lives.
Dr. Erica Mayer, director of breast cancer clinical research at Dana-Farber Cancer Institute in Boston, framed the stakes in the Roche release: patients progressing on endocrine therapies face narrowing options and declining quality of life. The recommended dose is 30 milligrams once daily, with or without food. Common side effects include inflammation in mouth or lung tissue, rash, fatigue, diarrhea, musculoskeletal pain and nausea, plus blood lab abnormalities; the label also warns of slow heart beat and harm to a developing embryo or fetus.
The price tag is steep: Roche told STAT the list price lands around $270,000 a year. Roche has said giredestrant could become its best-selling product ever, with analyst peak sales estimates spanning a few billion dollars to more than $10 billion annually if it wins broader breast cancer approvals. A decision on using it after surgery in higher-risk early-stage patients is due by Nov. 30.
TopicsFDA · Roche · giredestrant · everolimus · Wilserdly · FoundationOne Liquid CDx · Erica Mayer · Dana-Farber Cancer Institute
Source: clinicaladvisor.com
Written by AI from verified reporting.
More stories
- Health & science medicalxpress.com Caught by @ajayy30 0 viewsGut Bacterium's Sugar Burns Visceral Fat, Duke-Led Study Finds
- Health & science x.com 0 viewsFiona the hippo swallowed a knit cap, so the Cincinnati Zoo borrowed a horse farm's vibration plate
- Health & science scitechdaily.com 0 viewsFDA Approves First-in-Class Blood Pressure Pill That May Also Shield Kidneys
- Health & science finance.yahoo.com 2 sources 0 viewsFDA clears Regeneron's RNAi myasthenia drug at $410,000 a year

